Thomas A Mink, PA | |
1111 W Chase Ave, El Cajon, CA 92020 | |
(619) 515-2499 | |
Not Available |
Full Name | Thomas A Mink |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1111 W Chase Ave, El Cajon, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952339079 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Thomas A Mink, PA 823 Gateway Center Way, San Diego, CA 92102-4541 Ph: (619) 515-2300 | Thomas A Mink, PA 1111 W Chase Ave, El Cajon, CA 92020 Ph: (619) 515-2499 |
News Archive
Diabetes Mellitus (DM), a metabolic disorder that affects nearly 170 million people worldwide, is characterized by chronic hyperglycemia that disrupts carbohydrate fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. DM can cause long-term damage, dysfunction and even failure of various organs.
Of the 4.7 million Americans victimized annually by dog bites, more than half are children, according to the Centers for Disease Control and Prevention. Veterinarians, the U.S. Postal Service, the medical community and the insurance industry are working together to educate the public that dog bites are preventable.
The hospital environment remains the most common source of methicillin-resistant Staphylococcus aureus bacteria, show results from a systematic review and meta-analysis looking at nasal colonization in different groups of children.
Exelixis, Inc. today announced that it has completed the filing of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer.
› Verified 9 days ago